Needham L A, Van Dijk S, Pigott R, Edwards R M, Shepherd M, Hemingway I, Jack L, Clements J M
British Bio-technology Limited, Oxford, U.K.
Cell Adhes Commun. 1994 Jun;2(2):87-99. doi: 10.3109/15419069409004429.
Vascular cell adhesion molecule-1 (VCAM) is a cytokine-inducible member of the immunoglobulin superfamily which binds to the integrin VLA-4. VCAM is expressed predominantly on the vascular endothelium where it is involved in the recruitment of mononuclear cells and lymphocytes to sites of inflammation. Two forms of VCAM containing six and seven Ig domains (VCAM-6d; VCAM-7d) are generated by alternative splicing but the physiological significance of this is unknown. We have utilised VCAM deletion mutants, VCAM-transfected cell lines and monoclonal antibodies to assess the functional importance of the individual VCAM domains. We have identified two binding sites on VCAM-7d located in domains 1 and 4 that are involved in the adhesion of the U937 human myelomonocytic cell line. Adhesion to domain 1 is temperature-independent, inhibited by the anti-VCAM mAbs 4B2 or lE10, and insensitive to PMA activation. In contrast, adhesion to domain 4 is temperature sensitive, unaffected by mAbs 4B2 or lE10 and augmented by PMA. Adhesion to both domains can be totally inhibited by the anti-VLA-4 mAb, 2B4. The anti-VCAM mAb 4B2 inhibits adhesion of U937 cells to stably transfected VCAM-7d-CHO cells at 4 degrees C, but, at 37 degrees C the effect of 4B2 on adhesion is modest with incubation times of less than 60 minutes duration. With longer incubation times, its effectiveness gradually increases, so that by 2 hours > 75% of the response can be blocked. Co-incubation with PMA prevents this time-dependent enhancement of 4B2 efficacy but has no significant effect on the inhibitory activity of the anti-VLA-4 mAb 2B4. These data can be explained by postulating a two stage ligand-receptor interaction that involves activation-induced changes in the avidity of VLA-4 for domain 4 of VCAM.
血管细胞黏附分子-1(VCAM)是免疫球蛋白超家族中一种细胞因子诱导的成员,它与整合素VLA-4结合。VCAM主要在内皮细胞上表达,参与单核细胞和淋巴细胞向炎症部位的募集。通过可变剪接产生了两种形式的VCAM,分别含有六个和七个免疫球蛋白结构域(VCAM-6d;VCAM-7d),但其生理意义尚不清楚。我们利用VCAM缺失突变体、转染VCAM的细胞系和单克隆抗体来评估各个VCAM结构域的功能重要性。我们在VCAM-7d的结构域1和4中确定了两个结合位点,它们参与U937人骨髓单核细胞系的黏附。与结构域1的黏附不依赖温度,可被抗VCAM单克隆抗体4B2或1E10抑制,且对佛波酯(PMA)激活不敏感。相比之下,与结构域4的黏附对温度敏感,不受单克隆抗体4B2或1E10影响,并被PMA增强。对两个结构域的黏附均可被抗VLA-4单克隆抗体2B4完全抑制。抗VCAM单克隆抗体4B2在4℃时可抑制U937细胞与稳定转染的VCAM-7d-CHO细胞的黏附,但在37℃时,4B2对黏附的影响较小,孵育时间小于60分钟。随着孵育时间延长,其有效性逐渐增加,因此到2小时时,超过75%的反应可被阻断。与PMA共同孵育可阻止4B2功效的这种时间依赖性增强,但对抗VLA-4单克隆抗体2B4的抑制活性无显著影响。这些数据可以通过假设一种两阶段的配体-受体相互作用来解释,该相互作用涉及激活诱导的VLA-4对VCAM结构域4亲和力的变化。